Skip to main content

Table 4 Associations between presence of IgG antibodies to GLURP-R0 + R2 and parasite haplotypes in relation to treatment outcome.

From: Potential impact of host immunity on malaria treatment outcome in Tanzanian children infected with Plasmodium falciparum

  

GLURP-R0

GLURP-R2

Treatment and group SP

Presence of antibody/resistant haplotype*

TF

ACPR

TF

ACPR

1

+/-

2

4

1

6

2

-/-

4

3

5

2

3

+/+

6

7

9

7

4

-/+

22

2

19

1

AQ

     

1

+/-

1

7

0

8

2

-/-

2

5

3

4

3

+/+

4

12

3

11

4

-/+

12

6

13

7

  1. TF: Parasitological or clinical treatment failure, ACPR: Adequate clinical and parasitological response. SP: sulphadoxine-pyrimethamine, AQ: amodiaquine. *Number of patients with presence (+) or absence (-) of IgG antibodies to GLURP-R0 or R2 combined with resistant (+) or sensitive (-) genotypes associated with treatment outcome. Haplotypes were defined as resistant if parasites expressed the dhfr triple haplotype (CIRN) for the SP group or the CVIET haplotype for the AQ group.